Literature DB >> 10887511

Complex role of tumor cell transforming growth factor (TGF)-beta s on breast carcinoma progression.

K M Koli1, C L Arteaga.   

Abstract

Growth inhibition by the TGF-beta s has been extensively studied in both normal and transformed mammary epithelial cells. It has been proposed that loss of autocrine TGF-beta mediated growth regulation is a critical event in breast tumorigenesis and several lines of in vitro and in vivo data support this hypothesis. However, a positive association between the expression of TGF-beta s by tumor cells and the progression or maintenance of breast cancinoma cells has been observed in many studies in in vivo tumor models. Possible mechanisms for these growth enhancing effects of TGF-beta include immunosuppression mediated by tumor TGF-beta s, enhanced angiogenesis, increased peritumoral stroma formation, and cell adhesion. The net effect of tumor cell TGF-beta on the biology of breast carcinogenesis would depend on the balance between autocrine growth inhibition of mammary epithelial cells and these growth enhancing effects.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 10887511     DOI： 10.1007/BF02017393

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN： 1083-3021            Impact factor:   2.673


  59 in total

1.  Interaction of growth factors during progression towards steroid independence in T-47-D human breast cancer cells.

Authors:  R J Daly; R J King; P D Darbre
Journal:  J Cell Biochem       Date:  1990-07       Impact factor: 4.429

2.  Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines.

Authors:  G Zugmaier; B W Ennis; B Deschauer; D Katz; C Knabbe; G Wilding; P Daly; M E Lippman; R B Dickson
Journal:  J Cell Physiol       Date:  1989-11       Impact factor: 6.384

3.  Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol.

Authors:  B A Arrick; M Korc; R Derynck
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

4.  Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma.

Authors:  B I Dalal; P A Keown; A H Greenberg
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

5.  Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.

Authors:  S M Gorsch; V A Memoli; T A Stukel; L I Gold; B A Arrick
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

6.  Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues.

Authors:  Y Mizukami; A Nonomura; T Yamada; H Kurumaya; M Hayashi; N Koyasaki; T Taniya; M Noguchi; S Nakamura; F Matsubara
Journal:  Anticancer Res       Date:  1990 Sep-Oct       Impact factor: 2.480

7.  1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells.

Authors:  K Koli; J Keski-Oja
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

8.  Transcripts for transforming growth factors in human breast cancer: clinical correlates.

Authors:  P Barrett-Lee; M Travers; Y Luqmani; R C Coombes
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

9.  Extracellular matrix regulates expression of the TGF-beta 1 gene.

Authors:  C H Streuli; C Schmidhauser; M Kobrin; M J Bissell; R Derynck
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

10.  Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma.

Authors:  R A Walker; S J Dearing; B Gallacher
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640
View more
  7 in total

1.  Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.

Authors:  M A Lynch; T A Petrel; H Song; T J Knobloch; B C Casto; D Ramljak; L M Anderson; V DeGroff; G D Stoner; R W Brueggemeier; C M Weghorst
Journal:  Gene Expr       Date:  2001

2.  Estrogen receptors inhibit Smad3 transcriptional activity through Ap-1 transcription factors.

Authors:  Tracy Cherlet; Leigh C Murphy
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

Review 3.  Muc4/sialomucin complex in the mammary gland and breast cancer.

Authors:  K L Carraway; S A Price-Schiavi; M Komatsu; S Jepson; A Perez; C A Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

4.  Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.

Authors:  Atul Bedi; Xiaofei Chang; Kimberly Noonan; Vui Pham; Rishi Bedi; Elana J Fertig; Michael Considine; Joseph A Califano; Ivan Borrello; Christine H Chung; David Sidransky; Rajani Ravi
Journal:  Mol Cancer Ther       Date:  2012-08-27       Impact factor: 6.261

Review 5.  Transforming growth factor-beta and breast cancer: Lessons learned from genetically altered mouse models.

Authors:  L M Wakefield; Y A Yang; O Dukhanina
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

6.  Cellular potts modeling of tumor growth, tumor invasion, and tumor evolution.

Authors:  András Szabó; Roeland M H Merks
Journal:  Front Oncol       Date:  2013-04-16       Impact factor: 6.244

7.  Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?

Authors:  Josie Ursini-Siegel
Journal:  Front Oncol       Date:  2013-02-13       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.